PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10562768

Replacing testosterone in men.

View original source ↗Export metadata ↓

Abstract

Around 1 in 200 men have abnormally low levels of circulating testosterone that result in hypogonadism. Most of these men should be offered testosterone replacement therapy. Here we outline the rationale for such treatment and the different preparations available. We do not discuss the use of testosterone to induce pubertal development in prepubertal males with hypogonadism.

Explore related subjects

Hormone Replacement TherapyHumansHypogonadismMaleTestosteroneJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1999. Replacing testosterone in men.. https://doi.org/10.1136/dtb.1999.3713

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Postnatal thyroid hormone replacement in very preterm infants.

Transient hypothyroxinemia occurs frequently in very preterm infants and is caused by a combination of factors as immaturity of the hypothalamo-pituitary-thyroid system, loss of the maternal thyroxine (T4) contribution, immaturity of thyroid hormone metabolism, and neonatal illness. Thyroid hormone is important in maturation of the brain, but also of heart and lungs. Low neonatal T4 concentrations in plasma are related to worse clinical and neurodevelopmental outcome. Despite these relationships, only few randomized clinical trials have been performed to find out whether T4 supplementation can improve clinical and/or neurodevelomental outcome of preterm infants. The currently available evidence does not support use of supplemental T4 in all preterm infants. There are, however, indications that T4 might improve neurodevelopmental outcome in infants born before 27 to 29 weeks of gestation. Therefore, it is necessary that new trials are set up to further study the benefits of thyroid hormones given in the neonatal period of very preterm infants.

Hormone Replacement Therapy↗
PubMed2000

Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma.

Patients with previously treated thyroid carcinoma require lifelong monitoring for recurrent disease. Two diagnostic tests that play a central role in follow-up of these patients--radioiodine whole body scanning and serum thyroglobulin measurement--are most accurate during thyroid-stimulating hormone (TSH) stimulation. Temporary discontinuation of thyroid hormone therapy was previously the sole effective approach for TSH-stimulated testing. However, hormone withdrawal was associated with the morbidity of hypothyroidism and occasional tumor progression. The introduction of recombinant TSH (rTSH)-stimulated testing offers an alternative therapy. Recent clinical trials have shown that the sensitivity of combined rTSH-stimulated radioiodine scanning and serum thyroglobulin measurement has equivalent sensitivity to testing after thyroid hormone withdrawal. Furthermore, measurement of the rTSH-stimulated thyroglobulin concentration is a more sensitive way to detect residual thyroid cancer or normal tissue than thyroglobulin measurement on thyroid hormone therapy alone. The results of these trials are reviewed and strategies for implementing rTSH-mediated testing are presented.

Hormone Replacement Therapy↗